Sign in

    Kyle Aikman

    Research Analyst at JPMorgan Chase & Co.

    Kyle Aikman is an Equity Research Analyst at J.P. Morgan Securities LLC, specializing in the Healthcare Technology and Distribution sector, where he provides in-depth coverage and modeling for companies in hospitals and healthcare technology. He holds an undergraduate degree from the Isenberg School of Management and maintains a FINRA registration as a licensed broker. Since joining J.P. Morgan, Aikman has contributed to published forecasts and annual sector analyses, targeting revenue and EBITDA growth metrics for covered companies. His expertise is supported by strong academic credentials and industry licensing, reflecting a focused and data-driven approach to equity research in healthcare markets.

    Kyle Aikman's questions to Evolent Health (EVH) leadership

    Kyle Aikman's questions to Evolent Health (EVH) leadership • Q1 2025

    Question

    Kyle Aikman, on behalf of Annie Samuel at JPMorgan, requested more detail on the Q1 oncology cost trend, asking what the original assumption was and whether the lower-than-expected trend was driven by prevalence or cost of care.

    Answer

    Executive John Johnson clarified that all trend discussions are relative to the 12% normalized trend assumption. He attributed the favorable Q1 result to two factors: disease prevalence being up but less than expected, and cost-per-case also rising less than forecasted, partly due to the success of Evolent's clinical management interventions.

    Ask Fintool Equity Research AI